Livforsakringsbolaget Skandia Omsesidigt Raises Holdings in Bristol-Myers Squibb (NYSE:BMY)

Livforsakringsbolaget Skandia Omsesidigt grew its position in Bristol-Myers Squibb (NYSE:BMY) by 1.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 107,068 shares of the biopharmaceutical company’s stock after buying an additional 1,962 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Bristol-Myers Squibb were worth $5,490,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in BMY. Norges Bank bought a new position in shares of Bristol-Myers Squibb in the 4th quarter worth $1,873,696,000. Moneta Group Investment Advisors LLC raised its position in shares of Bristol-Myers Squibb by 114,228.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 21,469,785 shares of the biopharmaceutical company’s stock worth $1,544,751,000 after acquiring an additional 21,451,006 shares in the last quarter. Pacer Advisors Inc. raised its position in shares of Bristol-Myers Squibb by 48.0% in the 4th quarter. Pacer Advisors Inc. now owns 7,830,948 shares of the biopharmaceutical company’s stock worth $401,806,000 after acquiring an additional 2,540,360 shares in the last quarter. AustralianSuper Pty Ltd bought a new position in shares of Bristol-Myers Squibb in the 4th quarter worth $86,965,000. Finally, Cowa LLC increased its position in Bristol-Myers Squibb by 9,777.8% during the 1st quarter. Cowa LLC now owns 1,657,894 shares of the biopharmaceutical company’s stock valued at $1,211,000 after buying an additional 1,641,110 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on BMY shares. Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their target price for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their target price for the company from $68.00 to $60.00 in a research report on Wednesday, January 3rd. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Finally, Wells Fargo & Company dropped their price target on Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $61.12.

Bristol-Myers Squibb Price Performance

BMY stock traded down $0.43 during mid-day trading on Wednesday, reaching $47.83. 11,759,869 shares of the company’s stock were exchanged, compared to its average volume of 15,847,523. The company has a market cap of $96.94 billion, a price-to-earnings ratio of 12.50, a price-to-earnings-growth ratio of 1.46 and a beta of 0.39. The stock’s 50 day moving average is $51.27 and its 200 day moving average is $51.62. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31. Bristol-Myers Squibb has a 12-month low of $47.58 and a 12-month high of $70.93.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. The company had revenue of $11.48 billion for the quarter, compared to the consensus estimate of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. Bristol-Myers Squibb’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.82 earnings per share. On average, research analysts expect that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.02%. Bristol-Myers Squibb’s payout ratio is currently 62.18%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.